{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=103", "query": { "condition": "Neuroendocrine Tumours", "page": 103 }, "page_size": 10 }, "pagination": { "page": 103, "page_size": 10, "total_count": 2742, "total_pages": 275, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=104&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=102&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T18:27:29.894Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04010357", "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Extrapulmonary Small Cell Carcinoma" ], "interventions": [ { "name": "Abemaciclib,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 14, "start_date": "2020-01-13", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04010357" }, { "nct_id": "NCT01387581", "title": "Does the Aid of MelaFind Affect Clinical Management Decisions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "MELA Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 227, "start_date": "2011-10", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2014-11-14", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Irvington, New York", "locations": [ { "city": "Irvington", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387581" }, { "nct_id": "NCT00026520", "title": "Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 94, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026520" }, { "nct_id": "NCT03050268", "title": "Familial Investigations of Childhood Cancer Predisposition", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Leukemia", "Adenomatous Polyposis", "Adrenocortical Carcinoma", "AML", "BAP1 Tumor Predisposition Syndrome", "Carney Complex", "Choroid Plexus Carcinoma", "Constitutional Mismatch Repair Deficiency Syndrome", "Diamond-Blackfan Anemia", "DICER1 Syndrome", "Dyskeratosis Congenita", "Emberger Syndrome", "Familial Acute Myeloid Leukemia", "Familial Adenomatous Polyposis", "Fanconi Anemia", "Familial Cancer", "Familial Wilms Tumor", "Familial Neuroblastoma", "GIST", "Hereditary Breast and Ovarian Cancer", "Hereditary Paraganglioma-Pheochromocytoma Syndrome", "Hodgkin Lymphoma", "Juvenile Polyposis", "Li-Fraumeni Syndrome", "Lynch Syndrome", "MDS", "Melanoma Syndrome", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Neuroblastoma", "Neurofibromatosis Type 1", "Neurofibromatosis Type II", "Nevoid Basal Cell Carcinoma Syndrome", "Non Hodgkin Lymphoma", "Noonan Syndrome and Other Rasopathy", "Overgrowth Syndromes", "Pancreatic Cancer", "Peutz-Jeghers Syndrome", "Pheochromocytoma/Paraganglioma", "PTEN Hamartoma Tumor Syndrome", "Retinoblastoma", "Rhabdoid Tumor Predisposition Syndrome", "Rhabdomyosarcoma", "Rothmund-Thomson Syndrome", "Tuberous Sclerosis", "Von Hippel-Lindau Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1500, "start_date": "2017-04-06", "completion_date": "2037-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050268" }, { "nct_id": "NCT05653882", "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Melanoma", "Squamous Cell Carcinoma of Head and Neck", "Renal Cell Carcinoma" ], "interventions": [ { "name": "etakafusp alfa (AB248)", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Asher Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 552, "start_date": "2023-01-04", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 20, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05653882" }, { "nct_id": "NCT00533702", "title": "A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Melanoma" ], "interventions": [ { "name": "IMC-1121B (ramucirumab)", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2007-11", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-08-01", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 17, "location_summary": "Decatur, Alabama • Scottsdale, Arizona • Fresno, California + 12 more", "locations": [ { "city": "Decatur", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533702" }, { "nct_id": "NCT00667953", "title": "Study of Temzolomide and Gleevec in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Advanced Melanoma" ], "interventions": [ { "name": "Gleevec", "type": "DRUG" }, { "name": "Temodar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2003-01", "completion_date": "2011-03-09", "has_results": true, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667953" }, { "nct_id": "NCT02308020", "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Non-small Cell Lung Cancer", "Melanoma", "Brain Metastases" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2015-04-20", "completion_date": "2019-11-08", "has_results": true, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 19, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02308020" }, { "nct_id": "NCT07288203", "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2025-11-28", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288203" }, { "nct_id": "NCT01386580", "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Metastases", "Lung Cancer", "Breast Cancer", "Melanoma", "Malignant Glioma" ], "interventions": [ { "name": "2B3-101", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "2B3-101 60 mg/m2 every 4 weeks", "type": "DRUG" }, { "name": "2B3-101 50 mg/m2 every 3 weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BBB-Therapeutics B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2011-07", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-11-06T18:27:29.894Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01386580" } ] }